Marking: Certification that a device complies with EU MDR and may be marketed in the EU.

Post-Market Surveillance (PMS): Continuous monitoring of device performance after market approval.

These definitions highlight the comprehensive nature of MDR, covering devices independently or as part of drug-device combinations.

Regulatory Frameworks and EMA’s Role

The EU MDR framework integrates devices more tightly into pharmaceutical regulation:

• Medicinal Products with Devices: EMA evaluates medicinal products that include integral devices, such as prefilled pens or inhalers, as part of the Marketing Authorization Application (MAA).
• Stand-Alone Devices: Regulated by notified bodies under MDR, with EMA consultation for borderline cases.
• Companion Diagnostics (CDx): Governed under EU In Vitro Diagnostic Regulation (IVDR 2017/746) but often overlap with MDR in pharma submissions.
• Clinical Evaluation Reports (CER): Mandatory documentation demonstrating safety and performance of devices.

RA professionals must align pharma submissions with MDR conformity assessments to secure EU approvals.

Processes and Workflow for MDR Compliance

MDR compliance involves detailed workflows for RA teams:

1. Classification: Determine device class (I, IIa, IIb, III) under MDR rules.
2. Notified Body Engagement: Select and contract with an accredited notified body for conformity assessment.
3. Technical Documentation: Prepare device technical files including design, risk analysis, and performance testing.
4. Clinical Evaluation: Generate CER with supporting clinical evidence, often requiring post-market clinical follow-up.
5. Regulatory Submission: Include device documentation in CTD/eCTD when part of an MAA for a drug-device combination.
6. CE Marking: Obtain CE certification confirming compliance with MDR.
7. Post-Market Activities: Maintain PMS, vigilance reporting, and periodic safety update reports (PSURs).

This workflow demonstrates the multidisciplinary requirements of MDR compliance, spanning pharma, device engineering, and regulatory teams.

Case Study 1: Prefilled Syringe Combination Product

Case: A biologics company submitted an MAA for a prefilled syringe in 2023.

• Challenge: EMA required MDR compliance for the integral syringe component.
• Action: Company included technical documentation and engaged notified body for device certification.
• Outcome: EMA approved MAA contingent on ongoing PMS and vigilance reporting.
• Lesson Learned: Drug-device combination approvals require simultaneous compliance with MDR and pharma frameworks.

Case Study 2: EU MDR Implementation for Digital Health Device

Case: A medtech company sought CE marking for a digital health device under MDR in 2022.

• Challenge: New MDR rules required cybersecurity and software validation evidence.
• Action: Developed software validation protocols and risk management documentation.
• Outcome: Notified body granted CE certification under MDR 2017/745.
• Lesson Learned: MDR has expanded scope requiring additional evidence, particularly for digital and software-based devices.

Tools, Templates, and Systems for MDR Compliance

Compliance with MDR requires use of specialized tools:

• Technical Documentation Templates: MDR Annex II and III structures for device files.
• EMA and Notified Body Checklists: Used to ensure all required modules are included.
• Electronic Submission Platforms: EMA’s CESP and EU’s EUDAMED database.
• Risk Management Systems: ISO 14971-based frameworks for device risk assessment.
• PMS Tools: Systems to track post-market surveillance and vigilance reporting obligations.

These resources improve consistency, readiness, and efficiency for MDR submissions.

Common Challenges and Best Practices

MDR implementation has been challenging for both pharma and device companies:

• Notified Body Bottlenecks: Limited availability of accredited bodies causes delays.
• Increased Documentation: MDR requires far more technical and clinical data compared to MDD.
• Integration with Pharma Submissions: Ensuring consistency across drug CTD and device MDR files.
• Post-Market Complexity: New PMS and vigilance reporting requirements add ongoing obligations.

Best practices include early notified body engagement, integrating device and drug regulatory strategies, using harmonized templates, and maintaining robust PMS systems.

Latest Updates and Strategic Insights

By 2025, MDR implementation continues to evolve with several new developments:

• EUDAMED Database Expansion: Increasing transparency and data-sharing requirements.
• IVDR Alignment: Companion diagnostic rules overlapping with MDR requirements.
• Digital Health Emphasis: Stronger requirements for AI-based and connected devices.
• Global Influence: MDR becoming a reference standard for ROW markets adopting stricter device regulations.
• Inspection Trends: EMA and national authorities intensifying MDR compliance inspections.

Strategically, RA professionals must prepare for continued MDR evolution, harmonize pharma-device submissions, and embrace digital compliance tools for efficiency and readiness.

Conclusion

EU MDR has redefined device regulation in Europe, creating significant challenges and opportunities for pharma and medtech companies. By mastering classification, dossier integration, and notified body engagement, RA professionals can ensure compliance and market success. In 2025 and beyond, MDR compliance will remain central to global device strategy, shaping patient safety, innovation, and regulatory harmonization.